APA

Trimble C. L., Morrow M. P., Kraynyak K. A., Shen X., Dallas M., Yan J., Edwards L., Parker R. L., Denny L., Giffear M., Brown A. S., Marcozzi-Pierce K., Shah D., Slager A. M., Sylvester A. J., Khan A., Broderick K. E., Juba R. J., Herring T. A., Boyer J., Lee J., Sardesai N. Y., Weiner D. B. & Bagarazzi M. L. (20160113). Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial. : Lancet (London, England).

Chicago

Trimble Cornelia L, Morrow Matthew P, Kraynyak Kimberly A, Shen Xuefei, Dallas Michael, Yan Jian, Edwards Lance, Parker R Lamar, Denny Lynette, Giffear Mary, Brown Ami Shah, Marcozzi-Pierce Kathleen, Shah Divya, Slager Anna M, Sylvester Albert J, Khan Amir, Broderick Kate E, Juba Robert J, Herring Timothy A, Boyer Jean, Lee Jessica, Sardesai Niranjan Y, Weiner David B and Bagarazzi Mark L. 20160113. Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial. : Lancet (London, England).

Harvard

Trimble C. L., Morrow M. P., Kraynyak K. A., Shen X., Dallas M., Yan J., Edwards L., Parker R. L., Denny L., Giffear M., Brown A. S., Marcozzi-Pierce K., Shah D., Slager A. M., Sylvester A. J., Khan A., Broderick K. E., Juba R. J., Herring T. A., Boyer J., Lee J., Sardesai N. Y., Weiner D. B. and Bagarazzi M. L. (20160113). Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial. : Lancet (London, England).

MLA

Trimble Cornelia L, Morrow Matthew P, Kraynyak Kimberly A, Shen Xuefei, Dallas Michael, Yan Jian, Edwards Lance, Parker R Lamar, Denny Lynette, Giffear Mary, Brown Ami Shah, Marcozzi-Pierce Kathleen, Shah Divya, Slager Anna M, Sylvester Albert J, Khan Amir, Broderick Kate E, Juba Robert J, Herring Timothy A, Boyer Jean, Lee Jessica, Sardesai Niranjan Y, Weiner David B and Bagarazzi Mark L. Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial. : Lancet (London, England). 20160113.